Unicycive Therapeutics, Inc.
Unicycive Therapeutics is a biotech company founded in 2016 to accelerate healthcare innovation in overlooked areas like kidney disease.
Last updated September 2, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Unicycive Therapeutics, Inc. is a biotech company founded in 2016 to accelerate healthcare innovation in overlooked areas like kidney disease. The company focuses on closing urgent gaps in kidney care and has licensed technologies including oxylanthanum carbonate (OLC) and UNI-494. Unicycive went public on NASDAQ in July 2021 under the ticker UNCY.
History
Unicycive was founded in 2016 to accelerate healthcare innovation in overlooked areas like kidney disease. In 2018, it licensed its first two technologies, oxylanthanum carbonate (OLC) and UNI-494. In July 2021, Unicycive went public, listing on NASDAQ under the ticker symbol UNCY. In September 2021, it was added to the Russell Microcap Index. In October 2024, it successfully completed a Phase 1 study of UNI-494 in healthy volunteers.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/unicycive-therapeutics-inc · Editorial policy · How profiles are compiled